Arcus Q1 net loss $80M, cash $1.0B; multiple Ph3 domvanalimab trials enrolling

Arcus Biosciences, Inc.

2024-Q1 EPS reported -$1.09 revenue$25,000,000

Revenue $25M (up from $18M YoY); net loss $80M vs $68M in Q1 2022.
Cash, equivalents and securities $1.0B; expected to fund operations into 2026.
Four Phase 3 and two Phase 2 trials enrolling for domvanalimab combinations in lung and GI cancers.
AB521 (HIF-2α inhibitor) dose-escalation enrolling 100mg; Phase 2 combo study in ccRCC expected Q3 2023.
Three new drug candidates advancing to clinic: AB598 (anti-CD39) Q2 2023, AB801 (Axl inhibitor) H2 2023, AB375 (KIT inhibitor) early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcus Biosciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $25 million.

Period: the first quarter ended March 31, 2023
Revenue: $25 million
Result: reported results

Exact text from the filing

cash in research and development activities. Cash, cash equivalents and marketable securities on-hand are expected to be sufficient to fund operations into 2026. • Revenues were $25 million for first quarter 2023, compared to $18 million for the same period in 2022. In first quarter 2023, Arcus recognized $17 million in license and development service revenues for

View on SEC.gov

Browse all earnings releases →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.